Financial Data and Key Metrics Changes - The revenue for the first half of 2025 was PLN 17.3 billion, slightly down from the previous year, with a significant drop in compensation payments from PLN 2.1 billion to PLN 630 million [28][29] - EBITDA reached a historical high of PLN 4.2 billion, compared to previous years where such figures were only seen for the full year [29][30] - Net profit exceeded PLN 2 billion, with no impairment charges related to coal assets this year, contrasting with the previous year [30][31] - The net debt to EBITDA ratio improved significantly due to the increase in EBITDA, with financial debt decreasing by approximately PLN 1.5 billion year over year [31][38] Business Line Data and Key Metrics Changes - The distribution segment generated 60% of the group's EBITDA, amounting to nearly PLN 2.5 billion, driven by a higher regulatory asset base and a positive regulatory account [32][34] - The generation segment saw a positive surprise with increased margins due to lower coal prices and better balancing market revenue [35] - The renewables segment experienced a decline in revenue and EBITDA due to lower market prices and adverse weather conditions affecting production [35] Market Data and Key Metrics Changes - The share of renewables in the Polish energy mix remained stable at 28%, with a 17% increase in installed capacity for renewables [12][11] - National electricity consumption was slightly lower than the previous year, while production increased by 1.5%, resulting in a net export of 1 terawatt hour [11][12] - The average electricity price for 2025 was around PLN 488, with spot market prices at PLN 427 [18] Company Strategy and Development Direction - The company is focused on heat decarbonization, growth in distribution, and expansion in renewable energy sales [5][6] - A significant portion of CAPEX, estimated between PLN 100 billion to 130 billion, will be financed through preferential sources, with PLN 17 billion already secured [40][41] - The company is preparing for the 2027-2028 capacity market auction, emphasizing the need for social acceptance of energy transition projects [56][61] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in delivering on strategic promises, highlighting the importance of financial stability for future investments [57][58] - The outlook for EBITDA is expected to improve year over year, driven by better performance in generation and heat segments [54] - The company is actively engaging with local communities to ensure social acceptance of its projects, which is deemed crucial for successful implementation [61] Other Important Information - The company has increased its renewables grid connection capacity by 510 megawatts and installed 460,000 new remote readout meters in the first half of 2025 [26] - The regulatory asset base for distribution rose to PLN 24.6 billion, reflecting a PLN 2.7 billion increase from the previous year [25] - The company is committed to workforce development and improving customer service as part of its long-term strategy [60] Q&A Session Summary Question: What are the expectations for future EBITDA growth? - Management expects EBITDA to improve year over year, driven by better performance in generation and heat segments, despite a decline in supply volume [54][55] Question: How is the company addressing the challenges in the renewables segment? - The company is focusing on increasing its in-house development capabilities and expanding its project pipeline, particularly in wind and energy storage [52][48] Question: What steps are being taken to ensure social acceptance of energy transition projects? - Management emphasized the importance of engaging with local communities and demonstrating the benefits of projects to gain social approval [61]

Financial Data and Key Metrics Changes - The company expects profit results in Q1 to be significantly pressured by increased investment and the impact from the yogurt divestiture, with expectations of improvement in the back half of the year [9][60] - The profit performance in Q1 was better than expected, with gross margin benefiting from lighter inflation phasing and trade expense timing [57][58] Business Line Data and Key Metrics Changes - The company has strengthened its pound share in eight of its top ten categories and is holding pound share in the Pet segment [8][11] - New product volumes are up 25%, with strong performance expected in categories like baking and soup during key seasons [10][11] Market Data and Key Metrics Changes - The North America Retail category saw volume improvements in Q1, with the top ten categories performing slightly better than expected [91] - The company noted a shipment timing headwind in the Pet segment, impacting total company pounds in the quarter [29] Company Strategy and Development Direction - The company is focused on returning to profitable organic growth as the best way to create value for shareholders, with significant investments in innovation and new product launches [5][7] - The strategy includes adjusting base shelf prices and enhancing product offerings to meet consumer demand [47][48] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's approach, noting that while external factors impact the industry, many elements remain within the company's control [15][17] - The company anticipates continued pressure from inflation but expects to see improvements in the second half of the fiscal year [9][60] Other Important Information - The company is actively working on reformulating products to meet consumer preferences, including the removal of artificial dyes and other additives [74][78] - The company is leveraging technology for better demand planning and forecasting, which is expected to enhance marketing effectiveness [68][70] Q&A Session Summary Question: What is the outlook for volume growth? - Management expects volume growth to return by Q4, with current category volumes being flat but holding or gaining share in eight out of ten categories [22][23] Question: What are the trends in dog food and pet treats? - The core Pet business held pound share, with positive growth in Blue Life Protection Formula and Tiki Cat, while the Wilderness business needs improvement [32][34][36] Question: How is the company addressing pricing and competition? - The company is adjusting pricing strategies to remain competitive, particularly in the face of inflation and consumer demand for value [46][48] Question: What categories drove household penetration gains? - Household penetration improved in bars, fruit snacks, and cereals, driven by effective pricing adjustments and strong product innovation [64][66] Question: How is the company managing supply chain and demand planning? - The company is utilizing AI for better forecasting, allowing marketing teams to focus on demand generation rather than just forecasting [68][70] Question: What is the company's approach to reformulation and regulatory challenges? - The company is proactively reformulating products to align with consumer preferences and is confident in navigating regulatory changes [78][80]

Financial Data and Key Metrics Changes - Revenue increased by 70% compared to the previous year, with operating costs reduced by 54% [12][11] - The company raised over €8 million in capital, strengthening its balance sheet and simplifying its capital structure [14] - Total liabilities decreased by €4.3 million through note conversions and repayments, reducing outstanding notes to approximately €1.5 million [19] Business Line Data and Key Metrics Changes - Australia Gas secured engineering contracts for the next 18 months and over $1 million in recurring annual fuel sales [15] - Bright Hydrogen Solutions has won several tender offers and is advancing towards a €30 million investment vehicle [15][24] - The company recorded €6.9 million in revenues for the first half, with 55% from recurring fuel distribution and 45% from engineering contracts [16] Market Data and Key Metrics Changes - The Dubai market is experiencing rapid growth, driven by construction and infrastructure development, which is positively impacting the company's operations [27] - The company is on track to exceed its year-over-year growth average of 30% in Australia Gas [27] Company Strategy and Development Direction - The company aims to be a leader in both current energy markets and future clean energy solutions, leveraging both immediate cash flow and long-term innovation [5][7] - A dual approach is being employed to capture current energy needs while developing clean energy solutions [6][5] - The M&A strategy is focused on enhancing and diversifying the energy platform through strategic acquisitions [35][39] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges faced in 2024 but emphasized the successful turnaround and stabilization of the company in 2025 [10][41] - The company is focused on achieving sustainable profitability and significant revenue growth, targeting over $75 million in revenue by 2026 [44] Other Important Information - The company has successfully restored NASDAQ compliance and is actively pursuing strategic acquisitions [40][42] - Bright Hydrogen Solutions is expected to achieve breakeven within its first 12 to 15 months, targeting revenues of up to €5 million by 2026 [23] Q&A Session Summary Question: What are the key developments in the hydrogen sector? - Bright Hydrogen Solutions has secured agents agreements with leading hydrogen equipment providers and won several tenders, indicating strong market positioning [15][22] Question: How is the company addressing its financial challenges? - The company has significantly reduced operating costs and improved its balance sheet through capital raises and liability management [19][12] Question: What is the outlook for the Dubai market? - The Dubai market is one of the fastest-growing economies, with sustained demand for energy driven by construction and infrastructure development [27]

Financial Data and Key Metrics Changes - For the first half of 2025, the company reported total revenue of $4.9 million, primarily driven by collaborations with AstraZeneca and Sanofi, as well as governmental funding for research expenditures [28] - Operating expenses reached $30.3 million, with R&D expenses at $20.5 million, reflecting a 29% decrease compared to the prior year, while G&A expenses remained stable at $9.8 million [28] - As of June 30, 2025, the company had $70.4 million in cash, cash equivalents, and financial assets, providing a cash runway until the end of the third quarter of 2026 [28] Business Line Data and Key Metrics Changes - The company is focusing investments on three high-value clinical assets: IPH4502, Lacutamab, and Monalizumab, which are expected to create meaningful value [4][30] - IPH4502 is currently in phase one development, with enrollment progressing well and expected to complete by the end of Q1 2026 [11][14] - Lacutamab is close to completing the phase three protocol, with potential accelerated approval in Sézary syndrome anticipated by 2027 [21][25] Market Data and Key Metrics Changes - The company identified approximately 1,000 Sézary syndrome patients in the U.S., with around 300 new cases each year, representing a significant market opportunity for Lacutamab [24][25] - The total agreement with AstraZeneca for Monalizumab is worth up to $1.275 billion, with $450 million already received in upfront and milestone payments [27] Company Strategy and Development Direction - The company has made a strategic decision to streamline its organization and focus on high-value clinical assets to drive forward programs that can make a significant difference [4][30] - The company is actively working with investors and partners to secure funding for the phase three trial of Lacutamab, while also exploring options for IPH4502 [38][39] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in the strategic refocus and the potential of the clinical pipeline to deliver value for patients and shareholders [30] - The restructuring plan is fully embedded into the cash runway, ensuring financial visibility through the end of Q3 2026 [54] Other Important Information - The Chief Scientific Officer, Eric Vivier, will transition to a role as an advisor to the R&D Committee of the Board of Directors, ensuring continued collaboration [5] - The company is exploring the potential of IPH4502 in urothelial cancer patients who have become refractory to enfortumab vedotin, with a focus on addressing high unmet medical needs [41] Q&A Session Summary Question: What should we take away on the potential of targeting NK cells now that ANKET® assets are not included in your prioritization today? - Management clarified that while NK cells are not the main priority, they are still working on NK cell engagers and will base future decisions on clinical data [32][33] Question: Any commentary on where Sanofi is with the assets that they currently are developing? - Management indicated that Sanofi continues to progress the BCMA-targeted ANKET® and updates are expected soon [37] Question: Regarding the phase three start for Lacutamab, should we still assume that unless you have a partner signed up ahead of the start of the study, it'll still be a wait and watch? - Management confirmed they are actively working with investors and partners to keep options open for moving forward with Lacutamab [38] Question: Based on the preclinical data that you have generated so far, what potential indications do you think IPH4502 will be effective? - Management highlighted a focus on urothelial cancer patients who are refractory to enfortumab vedotin, with potential for accelerated market approval [41] Question: Can you provide an initial estimate of the investment requirements if you decide to go to trial without a partner? - Management stated they would not normally communicate specific costs but indicated it would be similar to other oncology phase 3 trials [56]

Financial Data and Key Metrics Changes - For the first half of 2025, the company reported total revenue of $4.9 million, primarily driven by collaborations with AstraZeneca and Sanofi, as well as governmental funding for research expenditures [29] - Operating expenses reached $30.3 million, with R&D expenses at $20.5 million, reflecting a 29% decrease compared to the prior year, while G&A expenses remained stable at $9.8 million [29] - As of June 30, 2025, the company had $70.4 million in cash, cash equivalents, and financial assets, providing a cash runway until the end of the third quarter of 2026 [29] Business Line Data and Key Metrics Changes - The company is focusing investments on three high-value clinical assets: IPH4502, Lacutamab, and Monalizumab, which are expected to create meaningful value and transform care [5][31] - IPH4502 is currently in phase one development, with enrollment progressing well and expected to complete by the end of Q1 2026 [12][15] - Lacutamab is close to finalizing the phase three protocol, with potential for accelerated approval in Sézary syndrome [16][21] Market Data and Key Metrics Changes - The company identified approximately 1,000 Sézary syndrome patients in the U.S., with around 300 new cases each year, representing a significant market opportunity for Lacutamab [24] - The total agreement for Monalizumab with AstraZeneca is worth up to $1.275 billion, with $450 million already received in upfront and milestone payments [28] Company Strategy and Development Direction - The company has made a strategic decision to streamline its organization and focus on high-value clinical assets, aligning its strategy, science, and investments [5][31] - The company is exploring partnerships and investor support to advance Lacutamab towards phase three, with a focus on maximizing value for both patients and shareholders [21][39] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in the strategic refocus and the potential of the clinical pipeline to deliver value for patients and shareholders [31] - The restructuring plan is fully embedded into the cash runway, ensuring financial visibility until the end of Q3 2026 [55] Other Important Information - The Chief Scientific Officer, Eric Vivier, will transition to a role as an advisor to the R&D Committee of the Board of Directors, ensuring continued collaboration [6] - The company is actively collecting additional market data for Lacutamab and plans to share insights at a focused investor event by the end of the year [26] Q&A Session Questions and Answers Question: What should we take away on the potential of targeting NK cells now that ANKET® assets are not included in your prioritization today? - Management clarified that while NK cells are not the main priority, they are still working on NK cell programs and will base future decisions on clinical data [33][35] Question: Any commentary on where Sanofi is with the assets that they currently are developing? - Management indicated that Sanofi continues to progress the BCMA-targeted ANKET® and updates are expected soon [38] Question: Regarding the phase three start for Lacutamab, should we still assume that unless you have a partner signed up ahead of the start of the study, it'll still be a wait and watch? - Management confirmed they are actively working with investors and partners to keep options open for advancing Lacutamab into phase three [39][40] Question: Based on the preclinical data that you have generated so far, what potential indications do you think IPH4502 will be effective? - Management highlighted that IPH4502 could be effective in urothelial cancer patients who became refractory to enfortumab vedotin, with potential for accelerated market approval [41][42] Question: Can you provide an update on how enrollment has been progressing for IPH4502? - Management reported that enrollment is going extremely well, with plans to finish by Q1 2026 and a pool of data expected from 50-60 patients [46][48]

Financial Data and Key Metrics Changes - For the first half of 2025, the company reported total revenue of EUR 4.9 million, primarily driven by collaborations with AstraZeneca and Sanofi, as well as governmental funding for research expenditures [29] - Operating expenses reached EUR 30.3 million, with EUR 20.5 million in R&D and EUR 9.8 million in G&A expenses; R&D expenses decreased by 29% compared to the prior year [29] - As of June 30, 2025, the company had EUR 70.4 million in cash, cash equivalents, and financial assets, providing a cash runway until the end of the third quarter of 2026 [29] Business Line Data and Key Metrics Changes - The company is focusing investments on three high-value clinical assets: IPH4502, lacutamab, and monalizumab, which are expected to create meaningful value [5][31] - IPH4502 is currently in phase one development, with enrollment on track to complete by the end of Q1 2026 [12] - Lacutamab has secured FDA breakthrough therapy designation and is preparing for phase III protocol submission [22][31] Market Data and Key Metrics Changes - The company identified approximately 1,000 Sézary syndrome patients in the U.S., with around 300 new cases each year, representing a significant market opportunity for lacutamab [25] - There are approximately 20,000 CTCL patients in the U.S., with an incidence of about 5,000 patients, suggesting a larger population than previously estimated [26] Company Strategy and Development Direction - The company has made a strategic decision to streamline its organization and focus on high-value clinical assets to drive forward programs that can make a significant difference [5][31] - The partnership with AstraZeneca for monalizumab is a significant value driver, with a total agreement worth up to $1.275 billion [28] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in the strategic refocus and the potential of the clinical pipeline to deliver value for patients and shareholders [31] - The restructuring plan is fully embedded into the cash runway, ensuring financial visibility until the end of Q3 2026 [54] Other Important Information - The Chief Scientific Officer responsibilities have been assumed by the COO following the departure of the CSO, who will continue to support the company as an advisor [6][7] Q&A Session Summary Question: What should we take away on the potential of targeting NK cells now that ANKET assets are not included in your prioritization today? - Management clarified that while NK cells are not the main priority, they are still working on NK cell programs and will base future decisions on clinical data [34][35] Question: Any commentary on where Sanofi is with the assets that they currently are developing? - Management indicated that Sanofi continues to progress the BCMA-targeted ANKET and expects updates in the near future [37] Question: Regarding the phase III start for lacutamab, should we still assume that unless you have a partner signed up ahead of the start of the study, it'll still be a wait and watch? - Management is actively working with investors and partners to keep options open for moving forward with lacutamab [38][39] Question: Based on the preclinical data that you have generated so far, what potential indications do you think IPH4502 will be effective? - Management highlighted a focus on urothelial cancer patients who became refractory or resistant to PADCEV, with potential for accelerated market approval [40][41] Question: Can you provide an initial estimate of the investment requirements if you decide to go to trial without a partner? - Management refrained from providing specific cost estimates but indicated that it would be similar to standard oncology phase III trials [56]

Financial Data and Key Metrics Changes - Revenue increased by 70% compared to the previous year, reaching €6,900,000 in the first half of 2025, primarily from gas operations [12][17] - Operating costs decreased by approximately 60%, coming in at just under €3,000,000, reflecting significant restructuring efforts [17][22] - The company successfully raised over $8,000,000 in 2025, strengthening its balance sheet and simplifying its capital structure [15][21] Business Line Data and Key Metrics Changes - Australia Gas secured engineering contracts for the next 18 months and generated over $1,000,000 in recurring annual fuel sales [16] - Bright Hydrogen Solutions has established agreements with leading hydrogen equipment providers and is in the process of closing several tender offers [16][24] - The company has a backlog of $4,500,000 in new central gas system projects, ensuring reliable revenues through 2026 [34] Market Data and Key Metrics Changes - The Dubai market is experiencing rapid growth, driven by construction and infrastructure development, which is positively impacting the company's operations [30] - The company services nearly 38,000 end customers in the region, with expectations to exceed last year's LPG sales [31] Company Strategy and Development Direction - The company aims to be a leader in both current energy markets and future clean energy solutions, leveraging both gas supply and hydrogen initiatives [5][49] - A dual approach is being employed to generate immediate revenue while investing in future-oriented clean energy solutions [7][48] - The company is actively pursuing strategic acquisitions to enhance and diversify its energy platform [39][43] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges faced in 2024, including risks of delisting from NASDAQ, but emphasized the successful turnaround achieved in 2025 [10][45] - The company is focused on achieving sustainable profitability and aims to drive revenue beyond $75,000,000 in 2026 [48] - Management expressed confidence in the growth trajectory, highlighting the importance of both organic growth and strategic acquisitions [49] Other Important Information - The company has successfully restored NASDAQ compliance and is now focused on securing suitable debt financing for future acquisitions [46] - Bright Hydrogen Solutions is expected to achieve breakeven within its first 12 to 15 months, targeting revenues of up to €5,000,000 by 2026 [25][27] Q&A Session Summary Question: What are the key developments in the hydrogen sector? - The company has secured various tenders for hydrogen projects and is in the final stages of contract negotiations for multiple projects [24] Question: How is the company addressing its financial challenges? - Management highlighted significant cost reductions and a successful capital raise that have strengthened the balance sheet [15][21] Question: What is the outlook for the Dubai gas market? - The Dubai market is expected to continue its rapid growth, driven by infrastructure development and increasing energy demand [30]

Financial Data and Key Metrics Changes - For the first half of 2025, the company reported total revenue of $4.9 million, primarily driven by collaborations with AstraZeneca and Sanofi, as well as governmental funding for research expenditures [31] - Operating expenses reached $30.3 million, with R&D expenses at $20.5 million, reflecting a 29% decrease compared to the prior year, while G&A expenses remained stable at $9.8 million [31] - As of June 30, 2025, the company had $70.4 million in cash, cash equivalents, and financial assets, providing a cash runway until the end of the third quarter of 2026 [31][33] Business Line Data and Key Metrics Changes - The company is focusing investments on three high-value clinical assets: IPH4502, Lacutamab, and Monalizumab, which are expected to create meaningful value [6][33] - IPH4502 is currently in phase one development, with enrollment on track to complete by the end of Q1 2026 [13][15] - Lacutamab has received FDA breakthrough therapy designation and is preparing for a phase three trial, with a clear regulatory pathway for accelerated approval in Sézary syndrome [17][22] Market Data and Key Metrics Changes - The company identified approximately 1,000 Sézary syndrome patients in the U.S., with around 300 new cases each year, representing a significant market opportunity for Lacutamab [26] - The total agreement with AstraZeneca for Monalizumab is worth up to $1.275 billion, with $450 million already received in upfront and milestone payments [29] Company Strategy and Development Direction - The company has made a strategic decision to streamline its organization and focus on high-value clinical assets to drive forward programs that can make a significant difference [6][33] - The company is actively working to secure financing for Lacutamab's phase three trial and is exploring partnerships to maximize value for both patients and shareholders [22][28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strategic refocus and the potential of the clinical pipeline to deliver value for patients and shareholders [33] - The company is committed to advancing its ADC pipeline and expects to report preliminary safety and activity data for IPH4502 in the first half of 2026 [15][33] Other Important Information - The Chief Scientific Officer, Eric Vivier, will transition to a full-time academic role but will continue to support the company as an advisor [7] - The company is exploring the potential of IPH4502 in various tumor types with significant medical needs beyond urothelial cancer [12][15] Q&A Session Summary Question: What should we take away on the potential of targeting NK cells now that ANKET® assets are not included in your prioritization today? - Management clarified that while NK cells are not the main priority, they are still working on NK cell programs and will base future decisions on clinical data [36] Question: Any commentary on where Sanofi is with the assets that they currently are developing? - Management indicated that Sanofi continues to progress the BCMA-targeted ANKET® and expects updates in the near future [40] Question: Should we still assume that unless you have a partner signed up ahead of the start of the study, it'll still be a wait and watch till you get a partner? - Management confirmed they are actively working with investors and partners to keep options open for moving forward with Lacutamab [41] Question: Based on the preclinical data that you have generated so far, what potential indications do you think IPH4502 will be effective? - Management highlighted a focus on urothelial cancer patients who became refractory to enfortumab vedotin, with potential for accelerated market approval [42] Question: How is enrollment progressing for IPH4502? - Management reported that enrollment is going extremely well, with plans to finish by Q1 2026 and a pool of data expected from 50-60 patients [48] Question: Does the new strategic focus mean the ANKET® assets will not be progressed irrespective of clinical data? - Management reiterated that decisions on ANKET® assets will be based on clinical data and market relevance [50]

Financial Data and Key Metrics Changes - Total revenue for Q4 fiscal year 2025 reached RMB 617.8 million, with a net income of RMB 108 million, resulting in a net profit margin of 17.5% [17][18] - Sales and marketing expenses improved significantly to 47.6% of revenue from 69.2% in the previous quarter [17][18] - Gross profit for the quarter was RMB 467.6 million, with a gross margin of 75.7%, down from 85.9% in the same period last year [19] Business Line Data and Key Metrics Changes - Revenue from the property business totaled RMB 65.8 million, accounting for 10.6% of total revenue [18] - Individual online learning services generated revenues of RMB 456.9 million, down from RMB 906.7 million in Q4 2024 [18] - Revenues from enterprise services were RMB 35.7 million, compared to RMB 56.6 million a year ago, due to a reduction in marketing services [18] Market Data and Key Metrics Changes - The company held over RMB 1 billion in cash and cash equivalents, providing a strong foundation for transitioning into the property business [6] - Online GMV exceeded RMB 18 million in August, which is over nine times that of April [10] Company Strategy and Development Direction - The company is transforming from a traffic-driven to a product-driven business model, focusing exclusively on high-growth property business [4][5] - A potential business restructuring is underway to divest all non-property businesses, allowing concentration of resources on the property market [5][14] - The strategy includes strengthening IP creation, driving agile execution, and delivering sustainable returns to shareholders [14][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth potential of the property market and the company's ability to scale its IP portfolio [22][23] - The company expects revenues from the property business to be in the range of RMB 100 million to RMB 110 million for Q1 FY 2026 and RMB 750 million to RMB 800 million for the full fiscal year 2026 [22][23] Other Important Information - The company has established a joint venture with Juehua Entertainment to leverage cross-industry resources for IP promotion and engagement [51][53] - The company plans to open three to five flagship stores by the end of the year, enhancing brand visibility and community engagement [12][35] Q&A Session Summary Question: Recent revenue run rate and confirmed order backlog - Management noted that the growth rate of the Makuku IP has been explosive, with sales of Cinnodle exceeding 300,000 boxes, indicating strong future performance [26][28] Question: Details on Last One's equity arrangements - The acquisition of Last One involves a mix of shares and long-term incentives, with a commitment to long-term collaboration and value creation [30] Question: Revenue guidance and market expectations - Management stated that the guidance for FY25 and FY26 was based on a prudent assessment of market conditions, with expectations for continued growth driven by strong product performance [32][34] Question: Pipeline for the education segment restructuring - Management confirmed a strong pipeline for the restructuring process, indicating confidence in the property business's performance [38][40] Question: Product strategy and new categories - The company has a structured roadmap for IP launches and is exploring new product categories, including smaller figures and plush products [44][48]

Financial Data and Key Metrics Changes - Total revenue for Q4 fiscal year 2025 reached RMB 617.8 million, with a net income of RMB 108 million, resulting in a net profit margin of 17.5% [17][18] - Sales and marketing expenses improved significantly to 47.6% of revenue from 69.2% in the previous quarter [17][18] - Gross profit for the quarter was RMB 467.6 million, with a gross margin of 75.7%, down from 85.9% in the same period last year [19] Business Line Data and Key Metrics Changes - Revenue from the property business totaled RMB 65.8 million, accounting for 10.6% of total revenue [18] - Individual online learning services generated revenues of RMB 456.9 million, down from RMB 906.7 million in Q4 2024, primarily due to decreases in skills upgrading and financial literacy courses [18] - Revenues from enterprise services were RMB 35.7 million, compared to RMB 56.6 million a year ago, due to a reduction in marketing services [18] Market Data and Key Metrics Changes - The company held over RMB 1 billion in cash and cash equivalents, providing a strong foundation for transitioning into the property business [6] - Online GMV exceeded RMB 18 million in August, which is over nine times that of April [10] Company Strategy and Development Direction - The company is restructuring to divest all non-property businesses to focus exclusively on the high-growth property market [4][5] - The strategy includes strengthening IP creation, driving agile execution, and delivering sustainable returns to shareholders [14][15] - The company aims to capitalize on the cultural transformation driven by young, digitally savvy consumers seeking emotional connections and unique collectible experiences [6][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth potential of the property market and the company's ability to scale its IP portfolio [22][23] - The company expects revenues from the property business to be in the range of RMB 100 million to RMB 110 million for Q1 FY 2026 and RMB 750 million to RMB 800 million for the full fiscal year 2026 [22][23] - Management highlighted strong demand for new IPs and a robust pipeline for future product launches [34][35] Other Important Information - The company has established a joint venture with Juehua Entertainment to leverage cross-industry resources for IP promotion and engagement [55] - The company is actively developing new product categories, including smaller size figures and plush products, set to debut in Q4 [49] Q&A Session Summary Question: Recent revenue run rate and confirmed order backlog - Management noted that the growth rate for the new IP, Cinnodle, has been explosive, with sales exceeding 300,000 boxes, indicating strong future performance [27][28] Question: Details on Last One's equity arrangement - Management explained that approximately 60% of the consideration for Last One's remaining equity was paid in newly issued shares, with 40% as long-term incentives vesting over eight years [30][31] Question: Guidance for future revenue targets - Management stated that the guidance for FY25 and FY26 was based on a prudent assessment of market conditions, with expectations for continued growth driven by strong product performance and channel expansion [33][34] Question: Pipeline for the education segment sale - Management confirmed a strong pipeline for the restructuring process, emphasizing confidence in the property business's performance [40] Question: Product strategy and new categories - Management outlined a clear roadmap for IP launches and plans to introduce new product categories, including mini versions of existing products [46][49]